1.

Record Nr.

UNINA9910826864403321

Autore

Coombs Joseph E. <1966-, >

Titolo

International strategy and market performance in new biotechnology firms / / Joseph E. Coombs

Pubbl/distr/stampa

New York : , : Routledge, , 2013

ISBN

1-317-73375-4

1-315-79085-8

1-317-73376-2

Edizione

[1st ed.]

Descrizione fisica

1 online resource (111 p.)

Collana

Transnational business and corporate culture

Disciplina

338.4/76606

338.476606

Soggetti

Biotechnology industries

New business enterprises

International business enterprises

International trade

Lingua di pubblicazione

Inglese

Formato

Materiale a stampa

Livello bibliografico

Monografia

Note generali

Description based upon print version of record.

Nota di bibliografia

Includes bibliographical references and index.

Nota di contenuto

Cover; Transnational Business and Corporate Culture; Title Page; Copyright Page; Dedication; Table of Contents; Preface; Acknowledgments; List of Tables and Figures; Chapter 1 Introduction; Chapter 2 Theory and Hypotheses; Biotechnology Research; Literature Review: International Entrepreneurship; Literature Review: Organizational Change; Hypotheses; Chapter 3 Methodology; Research Design; Sample Selection; Measures of Constructs, Model I; Measures of Constructs, Model II; Measures of Constructs, Model III; Chapter 4 Analysis and Results; Data Analysis; Descriptive Statistics

Direction of Change in International StrategyForeign Revenue as a Percentage of Total Revenue; Firm Market Value; Chapter 5 Discussion and Conclusions; Discussion of Results; Limitations of the Study; Future Research; Appendix A Firms Included in Study; Appendix B Sample Coding Sheet; References; Index

Sommario/riassunto

The issues addressed in this study are: What internal factors support changes in the international operations of new firms? and What effect do these changes have on the firm's structure, control system, and



market performance.To answer these questions, this work examines the internal resources and market performance of a set of publicly traded biotechnology firms. Findings support the view that new firms can enter international markets through a variety of strategies, including international joint ventures and subsidiaries. Changes in international operations also are found to enhance firm